GLUE

Monte Rosa Therapeutics, Inc.

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 7

Net loss of $44.5 million compared to a profit in the prior year period.

earnings miss

90%

bullishMay 7

Net proceeds of $323.8 million from a 2026 underwritten public offering.

capital raise

70%

bearishMay 7

Collaboration revenue plummeted 95% year-over-year while R&D expenses rose 38%.

margin compression

80%

bearishMay 7

Net loss of $44.5 million compared to a profit in the prior year period.

earnings miss

90%

bullishMay 7

Net proceeds of $323.8 million from a 2026 underwritten public offering.

capital raise

70%

bearishMay 7

Collaboration revenue plummeted 95% year-over-year while R&D expenses rose 38%.

margin compression

80%

bearishMay 7

Net loss of $44.5 million compared to a profit in the prior year period.

earnings miss

90%

bullishMay 7

Net proceeds of $323.8 million from a 2026 underwritten public offering.

capital raise

70%

bearishMay 7

Collaboration revenue plummeted 95% year-over-year while R&D expenses rose 38%.

margin compression

80%

bearishMay 7

Net loss of $44.5 million compared to a profit in the prior year period.

earnings miss

90%

bullishMay 7

Net proceeds of $323.8 million from a 2026 underwritten public offering.

capital raise

70%

bearishMay 7

Collaboration revenue plummeted 95% year-over-year while R&D expenses rose 38%.

margin compression

80%

bearishMay 7

Net loss of $44.5 million compared to a profit in the prior year period.

earnings miss

90%

bullishMay 7

Net proceeds of $323.8 million from a 2026 underwritten public offering.

capital raise

70%

bearishMay 7

Collaboration revenue plummeted 95% year-over-year while R&D expenses rose 38%.

margin compression

80%

bearishMay 7

Net loss of $44.5 million compared to a profit in the prior year period.

earnings miss

90%

bullishMay 7

Net proceeds of $323.8 million from a 2026 underwritten public offering.

capital raise

70%

bearishMay 7

Collaboration revenue plummeted 95% year-over-year while R&D expenses rose 38%.

margin compression

80%

bearishMay 7

Net loss of $44.5 million compared to a profit in the prior year period.

earnings miss

90%

bullishMay 7

Net proceeds of $323.8 million from a 2026 underwritten public offering.

capital raise

70%

bearishMay 7

Collaboration revenue plummeted 95% year-over-year while R&D expenses rose 38%.

margin compression

80%

Filing History

10-QMay 7, 2026

The Q1 2026 filing presents a classic biotech dichotomy: a fortress balance sheet versus a deteriorating income statement. While the $671.2 million in liquidity provides a generous runway into 2029, the sharp decline in quarterly revenue and the increase in operating losses highlight the inherent risks of the 'platform' model. The company is effectively trading current cash for future optionality, betting that its AI-driven discovery engine can produce a blockbuster candidate before the capital runs dry. The overall impact of the filing is a reduction in immediate bankruptcy risk but an increase in the pressure for clinical validation. The massive equity raise in early 2026 has bought management time, but it has also set a high bar for the next set of data readouts. Investors must now weigh the validity of the $5.4 billion Novartis milestone potential against the reality of a company that has yet to generate sustainable, non-episodic revenue.